Dr Roshan Agarwal MRCP PhD

Publications


Journals

  • Payne S; Burke D; Mansi J; Jones A; Norton A; Joffe J; Cunningham D; McVie G; et alAgarwal R. (1 Feb 2013). Discordance between cancer prevalence and training: a need for an increase in oncology education. CLINICAL MEDICINE. 13:50-56. Author weblink.
  • Shaboodien R; Diamantis N; Blagden S; Gabra H; Agarwal R. (Mar 2013). Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity. Int J Gynecol Cancer. 23:481-487. Author weblink DOI.
  • Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ. (10 Jan 2013). EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 31:280-286. Author weblink DOI.
  • Stemke-Hale K; Shipman K; Kitsou-Mylona I; de Castro DG; Hird V; Brown R; Flanagan J; Gabra H; et alMills GB; Agarwal R; El-Bahrawy M. (Apr 2013). Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. Mod Pathol. 26:544-552. Author weblink DOI.
  • Shaboodien R; Stansby G; Hunt BJ; Agarwal R. (Oct 2012). Unprovoked venous thromboembolism: assess for cancer. Lancet Oncol. 13:973-974. Author weblink DOI.
  • Stansby G; Agarwal R; Hunt B; Ballard S. (31 Jul 2012). NICE ON VTE DISEASES Authors' reply to Makowska-Webb, Byatt, D'Costa, and Hart. BRITISH MEDICAL JOURNAL. 345. Author weblink DOI.
  • Harding V; Fenu E; Medani H; Shaboodien R; Ngan S; Li HK; Burt R; Diamantis N; et alTuthill M; Blagden S; Gabra H; Urch CE; Moser S; Agarwal R. (4 Sep 2012). Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer. 107:925-930. Author weblink DOI.
  • Mckie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; et alAgarwal R; Shaposhnikov D; Wong JLS; Gungor H; Janczar S; El-Bahrawy M; Lam E-F; Chayen NE; Gabra H. (Feb 2012). The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer. Cancer Discovery. DOI.
  • Agarwal R; Harding V; Short D; Fisher RA; Sebire NJ; Harvey R; Patel D; Savage PM; et alLim AK; Seckl MJ. (13 Mar 2012). Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia. Br J Cancer. 106:1089-1094. Author weblink DOI.
  • Dutta B; Pusztai L; Qi Y; André F; Lazar V; Bianchini G; Ueno N; Agarwal R; et alWang B; Shiang CY; Hortobagyi GN; Mills GB; Symmans WF; Balázsi G. (13 Mar 2012). A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer. 106:1107-1116. Author weblink DOI.
  • Cheng KW; Agarwal R; Mitra S; Lee JS; Carey M; Gray JW; Mills GB. (Feb 2012). Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med. 4:125-141. Author weblink DOI.
  • Li HK; Harding V; Williamson R; Blagden S; Gabra H; Agarwal R. (10 Jan 2012). Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer. J Clin Oncol. 30:e19-e20. Author weblink DOI.
  • Stavraka C; Ford A; Ghaem-Maghami S; Crook T; Agarwal R; Gabra H; Blagden S. (Apr 2012). A study of symptoms described by ovarian cancer survivors. Gynecol Oncol. 125:59-64. Author weblink DOI.
  • Agarwal R; Teoh S; Short D; Harvey R; Savage PM; Seckl MJ. (14 Jan 2012). Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet. 379:130-135. Author weblink DOI.
  • Stronach EA; Chen M; Maginn EN; Agarwal R; Mills GB; Wasan H; Gabra H. (Nov 2011). DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia. 13:1069-1080. Author weblink.
  • Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; et alHennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H. (1 Jul 2011). HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 71:4412-4422. Author weblink DOI.
  • Carden CP; Agarwal R; Saran F; Judson IR. (Oct 2008). Eligibility of patients with brain metastases for phase I trials: time for a rethink?. Lancet Oncol. 9:1012-1017. Author weblink DOI.
  • Banerji U; Camidge DR; Verheul HM; Agarwal R; Sarker D; Kaye SB; Desar IM; Timmer-Bonte JN; et alEckhardt SG; Lewis KD; Brown KH; Cantarini MV; Morris C; George SM; Smith PD; van Herpen CM. (1 Mar 2010). The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 16:1613-1623. Author weblink DOI.
  • Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; et alWotherspoon A; Horwich A. (Mar 2007). The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 18:541-545. Author weblink DOI.
  • Vidot S; Witham J; Agarwal R; Greenhough S; Bamrah HS; Tigyi GJ; Kaye SB; Richardson A. (Jun 2010). Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal. 22:926-935. Author weblink DOI.
  • Agarwal R; Kaye SB. (Aug 2006). Expression profiling and individualisation of treatment for ovarian cancer. Curr Opin Pharmacol. 6:345-349. Author weblink DOI.
  • Park ES; Rabinovsky R; Carey M; Hennessy BT; Agarwal R; Liu W; Ju Z; Deng W; et alLu Y; Woo HG; Kim SB; Cheong JH; Garraway LA; Weinstein JN; Mills GB; Lee JS; Davies MA. (Feb 2010). Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther. 9:257-267. Author weblink DOI.
  • Tan DS; Agarwal R; Kaye SB. (Nov 2006). Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7:925-934. Author weblink DOI.
  • Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; et alAgarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB. (15 May 2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69:4116-4124. Author weblink DOI.
  • Gonzalez-Angulo AM; Stemke-Hale K; Palla SL; Carey M; Agarwal R; Meric-Berstam F; Traina TA; Hudis C; et alHortobagyi GN; Gerald WL; Mills GB; Hennessy BT. (1 Apr 2009). Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 15:2472-2478. Author weblink DOI.
  • Forster MD; Ormerod MG; Agarwal R; Kaye SB; Jackman AL. (Nov 2007). Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells. Cytometry A. 71:945-950. Author weblink DOI.
  • Witham J; Vidot S; Agarwal R; Kaye SB; Richardson A. (1 Jun 2008). Transient ectopic expression as a method to detect genes conferring drug resistance. Int J Cancer. 122:2641-2645. Author weblink DOI.
  • Agarwal R; Peters TJ; Coombes RC; Vigushin DM. (2002). Tamoxifen-related porphyria cutanea tarda. Med Oncol. 19:121-123. Author weblink DOI.
  • Carey MS; Agarwal R; Gilks B; Swenerton K; Kalloger S; Santos J; Ju Z; Lu Y; et alZhang F; Coombes KR; Miller D; Huntsman D; Mills GB; Hennessy BT. (15 May 2010). Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-beta Pathway Signaling Indicates Response to Primary Chemotherapy. CLINICAL CANCER RESEARCH. 16:2852-2860. Author weblink DOI.
  • Agarwal R; Carey M; Hennessy B; Mills GB. (Jun 2010). PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs. 11:615-628. Author weblink.
  • Agarwal R; Gourley C; Perren TJ; Reed N; Parkin DE; Carty K; Rustin GJ; Gabra H; et alPaul J; Gore ME; Kaye SB; Scottish Gynecological Cancers Trials Group. (Jul 2010). First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series. Eur J Cancer. 46:2020-2026. Author weblink DOI.
  • Agarwal R; Jurisica I; Mills GB; Cheng KW. (1 Nov 2009). The Emerging Role of the RAB25 Small GTPase in Cancer. TRAFFIC. 10:1561-1568. Author weblink DOI.
  • Schmid P; Nagai Y; Agarwal R; Hancock B; Savage PM; Sebire NJ; Lindsay I; Wells M; et alFisher RA; Short D; Newlands ES; Wischnewsky MB; Seckl MJ. (4 Jul 2009). Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. LANCET. 374:48-55. Author weblink DOI.
  • Agarwal R; Gonzalez-Angulo A-M; Myhre S; Carey M; Lee J-S; Overgaard J; Alsner J; Stemke-Hale K; et alLluch A; Neve RM; Kuo WL; Sorlie T; Sahin A; Valero V; Keyomarsi K; Gray JW; Borresen-Dale A-L; Mills GB; Hennessy BT. (1 Jun 2009). Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. CLINICAL CANCER RESEARCH. 15:3654-3662. Author weblink DOI.
  • Lo SK; Montgomery JN; Blagden S; McNeish IA; Agarwal R; Suntharalingam J; Seckl MJ; Newlands ES. (12 Jun 1999). Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics. LANCET. 353:2038-2039. Author weblink DOI.
  • Agarwal R; Seckl MJ; Nelstrop A; Rustin GJS. (1 Jul 1999). A phase II study of sequential carboplatin (C), paclitaxel (P) and topetecan (T) in patients with previously untreated advanced ovarian cancer. BRITISH JOURNAL OF CANCER. 80:107-107. Author weblink.
  • Agarwal R; Strickland S; Foskett M; McNeish IA; Newlands ES; Seckl MJ. (1 Jul 2000). A study of the safety of increased folinic acid (FA) rescue for methotrexate (MTX) toxicity in patients with persistent trophoblastic disease (PTD). BRITISH JOURNAL OF CANCER. 83:80-80. Author weblink.
  • McNeish IA; Kanfer EJ; Haynes R; Agarwal R; Harland SJ; Newlands ES; Seckl MJ. (1 Jul 2000). Paclitaxel-containing high dose chemotherapy for relapsed or refractory germ cell tumours. BRITISH JOURNAL OF CANCER. 83:28-28. Author weblink.
  • Agarwal R; Strickland S; McNeish IA; Foskett M; Patel D; Boultbee J; Newlands ES; Seckl MJ. (1 Jul 2001). Tumour vascularity assessed using Doppler ultrasound predicts the risk of resistance to methotrexate chemotherapy in gestational trophoblastic tumours. BRITISH JOURNAL OF CANCER. 85:26-26. Author weblink.
  • Guppy AE; Nelstrop A; Agarwal R; Seckl MJ; Rustin GJS. (1 Jun 2002). A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. BRITISH JOURNAL OF CANCER. 86:S44-S44. Author weblink.
  • Tripuraneni G; Agarwal R. (1 May 2003). Management of pilondial sinus (PS): a meta-analysis. ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND. 85:211-211. Author weblink.
  • Guppy AE; Nelstrop AE; Foster T; Agarwal R; Seckl MJ; Rustin GJS. (23 Feb 2004). A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. BRITISH JOURNAL OF CANCER. 90:810-814. Author weblink DOI.
  • Lim AK; Agarwal R; Seckl MJ; Newlands ES; Barrett NK; Mitchell AW. (Mar 2002). Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology. 222:640-644. Author weblink.
  • Agarwal R; Strickland S; McNeish IA; Patel DC; Foskett M; Boultbee JE; Newlands ES; Seckl MJ. (May 2002). Doppler ultrasonography of the uterine artery and the response to chemotherapy in patients with gestational trophoblastic tumors. Clin Cancer Res. 8:1142-1147. Author weblink.
  • Murugaesu N; Schmid P; Dancey G; Agarwal R; Holden L; McNeish I; Savage PM; Newlands ES; et alRustin GJ; Seckl MJ. (20 Oct 2006). Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 24:4862-4866. Author weblink DOI.

Conferences

  • Witney TH; Carroll LS; Alam IS; Sala R; Agarwal R; Aboagye EO. Noninvasive imaging of tumor glycogen storage by F-18-NFTG positron emission tomography. AACR/SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy, 27 Feb 2013 - 2 Mar 2013. 54:27-27. SOC NUCLEAR MEDICINE INC (1 Feb 2013). Author weblink.
  • Stavraka C; MacLaran K; Gabra H; Agarwal R; Ghaem-Maghami S; Taylor A; Dhillo W; Panay N; et alBlagden S. A study to evaluate the cause of bone demineralisation in gynaecological cancer survivors. British Gynaecological Cancer Society Annual Scientific Meeting 2012, 5 Jul 2012 - 6 Jul 2012. (Jul 2012).
  • Evans TRJ; Propper DJ; Anthoney DA; Mansoor W; Eatock MM; Ford D; Agarwal R; Thomson D; et alMiwa M. Phase IIa Study of TP300 as 1st-line Monotherapy in Patients With Advanced Gastric (GC) or Gastro-oesophageal Junction (GOJ) Carcinoma. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, 23 Sep 2011 - 27 Sep 2011. 47:S468-S469. ELSEVIER SCI LTD (1 Sep 2011). Author weblink.
  • McKie A; Vaughan S; Okon I; Zanini E; Al-Jayoosi F; Agarwal R; Lam EWF; Gabra H. The OPCML tumour suppressor functions as a repressor-adaptor, negatively regulating receptor tyrosine kinases in ovarian cancer. 21st Meeting of the European-Association-for-Cancer-Research, 26 Jun 2010 - 29 Jun 2010. 8:108-108. PERGAMON-ELSEVIER SCIENCE LTD (1 Jun 2010). Author weblink.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook